Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$137.93 /

-4.405 (-3.09%)

18:02
04/11/21
04/11
18:02
04/11/21
18:02

Alnylam presents late-breaking data from ongoing Phase 1 study of ALN-AGT

Alnylam Pharmaceuticals announced interim results from the ongoing Phase 1 study of ALN-AGT, a subcutaneous investigational RNAi therapeutic targeting liver-expressed angiotensinogen for the treatment of hypertension. ALN-AGT treatment was associated with dose-dependent knockdown of AGT and reductions in blood pressure with a durability that supports the potential for a once quarterly or biannual dosing regimen, and was found to be generally safe and well tolerated. Eighty-four patients with hypertension were randomized in this double-blind, placebo-controlled, single ascending dose study evaluating the safety, tolerability and preliminary pharmacokinetic and pharmacodynamic activity of ALN-AGT. Patients, who were either treatment naive or had discontinued other anti-hypertensive medications prior to study entry, enrolled in ascending dose cohorts of 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, 400 mg or 800 mg ALN-AGT. Patients treated with single doses of ALN-AGT at 100 mg or higher experienced durable reductions in serum AGT of more than 90 percent through 12 weeks. In the 800 mg dose cohort, all patients experienced reductions in serum AGT of 96 - 98 percent at Week 12. Concomitant reductions in BP were observed with AGT knockdown, with clinically meaningful mean reductions in 24-hour systolic blood pressure of greater than 10 mm Hg observed at Week 8 after single doses of 100 mg or higher. At 800 mg, mean reductions in 24-hour SBP of 17 mm Hg were observed at Week 8 and sustained through Week 12. All data are as of a February 25, 2021 cut-off date. Suboptimal BP control remains the most common attributable risk factor for cardiovascular disease and cerebrovascular disease, and a leading cause of chronic kidney disease progression. These durable pharmacologic effects of ALN-AGT may support tonic control of BP with once quarterly and potentially biannual dosing. Less frequent dosing than available with current treatment options may help achieve improved medication adherence, an important part of maintaining BP control. ALN-AGT was shown to be generally well tolerated with an acceptable safety profile that supports advancement into Phase 2 studies. Most adverse events were mild or moderate in severity and resolved without intervention, with the most common AE consisting of mild and transient injection site reactions in 5 out of 56 patients receiving ALN-AGT. There were no clinically significant elevations in serum alanine aminotransferase, serum creatinine or serum potassium, and no patient required intervention for hypotension. There were no treatment-related serious AEs, deaths or AEs leading to study withdrawal.

  • 12

    Apr

  • 18

    May

  • 24

    May

ALNY Alnylam
$137.93 /

-4.405 (-3.09%)

02/22/21 Guggenheim
Alnylam downgraded to Neutral from Buy at Guggenheim
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 Barclays
Alnylam price target raised to $196 from $162 at Barclays
02/12/21 Citi
Alnylam downgraded to Neutral from Buy at Citi

TODAY'S FREE FLY STORIES

Hot Stocks
Department of Commerce imposes duties on silicon metal imports from Malaysia » 09:07
06/21/21
06/21
09:07
06/21/21
09:07
GSM

Ferroglobe

$5.40 /

+0.11 (+2.08%)

Globe Specialty Metals…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GSM Ferroglobe
$5.40 /

+0.11 (+2.08%)

Hot Stocks
Synopsys to acquire semiconductors, flat panel display solutions from BISTel » 09:07
06/21/21
06/21
09:07
06/21/21
09:07
SNPS

Synopsys

$265.81 /

+0.61 (+0.23%)

Synopsys announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SNPS Synopsys
$265.81 /

+0.61 (+0.23%)

SNPS Synopsys
$265.81 /

+0.61 (+0.23%)

06/01/21 Rosenblatt
Synopsys initiated with a Buy at Rosenblatt
02/18/21 DA Davidson
Synopsys price target raised to $335 from $285 at DA Davidson
02/18/21 Needham
Synopsys price target raised to $310 from $275 at Needham
02/18/21 Credit Suisse
Synopsys price target raised to $300 from $265 at Credit Suisse
SNPS Synopsys
$265.81 /

+0.61 (+0.23%)

SNPS Synopsys
$265.81 /

+0.61 (+0.23%)

SNPS Synopsys
$265.81 /

+0.61 (+0.23%)

Recommendations
PayPal's announced price increase already in guidance, says BofA » 09:06
06/21/21
06/21
09:06
06/21/21
09:06
PYPL

PayPal

$283.42 /

+5.345 (+1.92%)

BofA analyst Jason…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PYPL PayPal
$283.42 /

+5.345 (+1.92%)

PYPL PayPal
$283.42 /

+5.345 (+1.92%)

06:29 Today Barclays
PayPal price increase to bring 2022 earnings upside, says Barclays
05/07/21 BMO Capital
PayPal price target raised to $256 from $241 at BMO Capital
05/07/21 Oppenheimer
PayPal price target raised to $322 from $310 at Oppenheimer
05/06/21 Oppenheimer
PayPal price target raised to $322 from $310 at Oppenheimer
PYPL PayPal
$283.42 /

+5.345 (+1.92%)

PYPL PayPal
$283.42 /

+5.345 (+1.92%)

PYPL PayPal
$283.42 /

+5.345 (+1.92%)

PYPL PayPal
$283.42 /

+5.345 (+1.92%)

Hot Stocks
Select Medical, Community Health partner to acquire Curahealth Tucson » 09:06
06/21/21
06/21
09:06
06/21/21
09:06
SEM

Select Medical

$40.82 /

-1.49 (-3.52%)

, CYH

Community Health

$14.78 /

-0.68 (-4.40%)

Select Medical (SEM) and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SEM Select Medical
$40.82 /

-1.49 (-3.52%)

CYH Community Health
$14.78 /

-0.68 (-4.40%)

SEM Select Medical
$40.82 /

-1.49 (-3.52%)

05/21/21 Deutsche Bank
Select Medical price target raised to $48 from $46 at Deutsche Bank
05/13/21 Benchmark
Select Medical price target raised to $44 from $40 at Benchmark
05/10/21 Deutsche Bank
Select Medical price target raised to $46 from $42 at Deutsche Bank
02/26/21 BofA
Select Medical upgraded to Buy from Underperform at BofA
CYH Community Health
$14.78 /

-0.68 (-4.40%)

06/10/21 RBC Capital
Community Health upgraded to Outperform from Sector Perform at RBC Capital
05/05/21
Fly Intel: Top five analyst upgrades
05/05/21 Jefferies
Community Health upgraded to Buy on improved fundamentals at Jefferies
05/05/21 Jefferies
Community Health upgraded to Buy from Hold at Jefferies
SEM Select Medical
$40.82 /

-1.49 (-3.52%)

CYH Community Health
$14.78 /

-0.68 (-4.40%)

CYH Community Health
$14.78 /

-0.68 (-4.40%)

SEM Select Medical
$40.82 /

-1.49 (-3.52%)

CYH Community Health
$14.78 /

-0.68 (-4.40%)

CYH Community Health
$14.78 /

-0.68 (-4.40%)

Hot Stocks
Cassava Sciences expects cash to support Phase 3 program of simufilam » 09:05
06/21/21
06/21
09:05
06/21/21
09:05
SAVA

Cassava Sciences

$79.82 /

+1.265 (+1.61%)

As of March 31, Cassava…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

04/27/21 B. Riley
B. Riley starts Cassava Sciences at Buy on Alzheimer's focus
04/27/21 B. Riley
Cassava Sciences initiated with a Buy at B. Riley
03/17/21 JonesTrading
JonesTrading starts Alzheimer's 'pure play' Cassava Sciences at Buy
03/17/21 JonesTrading
Cassava Sciences initiated with a Buy at JonesTrading
SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

  • 13
    Nov
SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

Hot Stocks
Cassava Sciences to present SavaDx dataset at AAIC » 09:05
06/21/21
06/21
09:05
06/21/21
09:05
SAVA

Cassava Sciences

$79.82 /

+1.265 (+1.61%)

SavaDx is an…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

04/27/21 B. Riley
B. Riley starts Cassava Sciences at Buy on Alzheimer's focus
04/27/21 B. Riley
Cassava Sciences initiated with a Buy at B. Riley
03/17/21 JonesTrading
JonesTrading starts Alzheimer's 'pure play' Cassava Sciences at Buy
03/17/21 JonesTrading
Cassava Sciences initiated with a Buy at JonesTrading
SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

  • 13
    Nov
SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

Hot Stocks
Select Medical signs definitive agreement to acquire Acuity Healthcare » 09:05
06/21/21
06/21
09:05
06/21/21
09:05
SEM

Select Medical

$40.82 /

-1.49 (-3.52%)

Select Medical announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SEM Select Medical
$40.82 /

-1.49 (-3.52%)

SEM Select Medical
$40.82 /

-1.49 (-3.52%)

05/21/21 Deutsche Bank
Select Medical price target raised to $48 from $46 at Deutsche Bank
05/13/21 Benchmark
Select Medical price target raised to $44 from $40 at Benchmark
05/10/21 Deutsche Bank
Select Medical price target raised to $46 from $42 at Deutsche Bank
02/26/21 BofA
Select Medical upgraded to Buy from Underperform at BofA
SEM Select Medical
$40.82 /

-1.49 (-3.52%)

SEM Select Medical
$40.82 /

-1.49 (-3.52%)

Hot Stocks
Cassava Sciences to initiate Phase 3 program of simufilam in 2H21 » 09:04
06/21/21
06/21
09:04
06/21/21
09:04
SAVA

Cassava Sciences

$79.82 /

+1.265 (+1.61%)

Cassava Sciences plans to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

04/27/21 B. Riley
B. Riley starts Cassava Sciences at Buy on Alzheimer's focus
04/27/21 B. Riley
Cassava Sciences initiated with a Buy at B. Riley
03/17/21 JonesTrading
JonesTrading starts Alzheimer's 'pure play' Cassava Sciences at Buy
03/17/21 JonesTrading
Cassava Sciences initiated with a Buy at JonesTrading
SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

  • 13
    Nov
SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

Initiation
Paymentus initiated with a Neutral at JPMorgan » 09:04
06/21/21
06/21
09:04
06/21/21
09:04
PAY

Paymentus

/

+

JPMorgan analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PAY Paymentus
/

+

07:31 Today Raymond James
Paymentus initiated with an Outperform at Raymond James
06:45 Today Baird
Paymentus risk/reward seen positive, Baird starts with Outperform
06:35 Today Wells Fargo
Paymentus initiated with an Overweight at Wells Fargo
06:34 Today Wolfe Research
Paymentus initiated with an Outperform at Wolfe Research
  • 26
    May
PAY Paymentus
/

+

Downgrade
BofA downgrades CNX Resources to Underperform on oil over gas preference » 09:04
06/21/21
06/21
09:04
06/21/21
09:04
CNX

CNX Resources

$13.15 /

-0.615 (-4.47%)

BofA analyst John Abbott…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CNX CNX Resources
$13.15 /

-0.615 (-4.47%)

CNX CNX Resources
$13.15 /

-0.615 (-4.47%)

08:05 Today BofA
CNX Resources downgraded to Underperform from Neutral at BofA
03/30/21
Fly Intel: Top five analyst downgrades
03/30/21 Truist
CNX Resources downgraded to Hold from Buy at Truist
03/30/21 Truist
CNX Resources downgraded to Hold from Buy at Truist
CNX CNX Resources
$13.15 /

-0.615 (-4.47%)

CNX CNX Resources
$13.15 /

-0.615 (-4.47%)

Hot Stocks
Cassava Sciences targets enrollment of 100 or more subjects for CMS » 09:03
06/21/21
06/21
09:03
06/21/21
09:03
SAVA

Cassava Sciences

$79.82 /

+1.265 (+1.61%)

In May 2021, Cassava…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

04/27/21 B. Riley
B. Riley starts Cassava Sciences at Buy on Alzheimer's focus
04/27/21 B. Riley
Cassava Sciences initiated with a Buy at B. Riley
03/17/21 JonesTrading
JonesTrading starts Alzheimer's 'pure play' Cassava Sciences at Buy
03/17/21 JonesTrading
Cassava Sciences initiated with a Buy at JonesTrading
SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

  • 13
    Nov
SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

Hot Stocks
Luby's signs agreement to sell Cafeteria Restaurant operations to Calvin Gin » 09:03
06/21/21
06/21
09:03
06/21/21
09:03
LUB

Luby's

$3.72 /

+ (+0.00%)

Luby's announced the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LUB Luby's
$3.72 /

+ (+0.00%)

Downgrade
BofA downgrades Range Resources to Underperform on oil over gas preference » 09:03
06/21/21
06/21
09:03
06/21/21
09:03
RRC

Range Resources

$14.14 /

+0.015 (+0.11%)

BofA analyst Doug Leggate…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RRC Range Resources
$14.14 /

+0.015 (+0.11%)

RRC Range Resources
$14.14 /

+0.015 (+0.11%)

08:04 Today BofA
Range Resources downgraded to Underperform from Neutral at BofA
06/14/21 Tudor Pickering
Range Resources downgraded to Hold from Buy at Tudor Pickering
06/10/21 MKM Partners
Range Resources downgraded to Neutral at MKM Partners on valuation
06/10/21 RBC Capital
Range Resources upgraded to Outperform from Sector Perform at RBC Capital
RRC Range Resources
$14.14 /

+0.015 (+0.11%)

RRC Range Resources
$14.14 /

+0.015 (+0.11%)

Hot Stocks
Cassava to announce results of interim analysis of open-label study at AAIC » 09:02
06/21/21
06/21
09:02
06/21/21
09:02
SAVA

Cassava Sciences

$79.82 /

+1.265 (+1.61%)

Cassava Sciences plans to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

04/27/21 B. Riley
B. Riley starts Cassava Sciences at Buy on Alzheimer's focus
04/27/21 B. Riley
Cassava Sciences initiated with a Buy at B. Riley
03/17/21 JonesTrading
JonesTrading starts Alzheimer's 'pure play' Cassava Sciences at Buy
03/17/21 JonesTrading
Cassava Sciences initiated with a Buy at JonesTrading
SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

  • 13
    Nov
SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

Hot Stocks
Lydall trading resumes  09:02
06/21/21
06/21
09:02
06/21/21
09:02
LDL

Lydall

$33.33 /

-1.24 (-3.59%)

 
ShowHide Related Items >><<
LDL Lydall
$33.33 /

-1.24 (-3.59%)

LDL Lydall
$33.33 /

-1.24 (-3.59%)

12/21/20 Sidoti
Lydall downgraded to Neutral from Buy at Sidoti
10/20/20 Sidoti
Lydall re-initiated with a Buy at Sidoti
LDL Lydall
$33.33 /

-1.24 (-3.59%)

Initiation
Northern Oil and Gas resumed with a Buy at BofA » 09:01
06/21/21
06/21
09:01
06/21/21
09:01
NOG

Northern Oil and Gas

/

+

BofA analyst Alex Vrabel…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
NOG Northern Oil and Gas
/

+

NOG Northern Oil and Gas
/

+

06/18/21 Raymond James
Northern Oil and Gas price target raised to $27 from $24 at Raymond James
06/17/21 Stifel
Northern Oil and Gas' accretive acquisitions a positive, says Stifel
05/10/21 Truist
Northern Oil and Gas price target raised to $25 from $20 at Truist
04/16/21 Citi
Northern Oil and Gas initiated with a Buy at Citi
NOG Northern Oil and Gas
/

+

  • 17
    Jun
  • 05
    Feb
Hot Stocks
Cassava Sciences completes enrollment in open-label study of simufilam » 09:00
06/21/21
06/21
09:00
06/21/21
09:00
SAVA

Cassava Sciences

$79.82 /

+1.265 (+1.61%)

In March 2020, Cassava…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

04/27/21 B. Riley
B. Riley starts Cassava Sciences at Buy on Alzheimer's focus
04/27/21 B. Riley
Cassava Sciences initiated with a Buy at B. Riley
03/17/21 JonesTrading
JonesTrading starts Alzheimer's 'pure play' Cassava Sciences at Buy
03/17/21 JonesTrading
Cassava Sciences initiated with a Buy at JonesTrading
SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

  • 13
    Nov
SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

SAVA Cassava Sciences
$79.82 /

+1.265 (+1.61%)

Upgrade
Cimarex Energy upgraded to Buy on oil price strength at BofA » 09:00
06/21/21
06/21
09:00
06/21/21
09:00
XEC

Cimarex Energy

/

+

As previously reported,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
XEC Cimarex Energy
/

+

XEC Cimarex Energy
/

+

08:05 Today BofA
Cimarex Energy upgraded to Buy from Neutral at BofA
06/18/21 Morgan Stanley
Cimarex Energy downgraded to Equal Weight from Overweight at Morgan Stanley
06/15/21 UBS
Cimarex Energy downgraded to Neutral from Buy at UBS
06/03/21 Barclays
Cimarex Energy downgraded to Equal Weight from Overweight at Barclays
XEC Cimarex Energy
/

+

XEC Cimarex Energy
/

+

XEC Cimarex Energy
/

+

Upgrade
Marathon Oil upgraded to Neutral on oil price strength at BofA » 09:00
06/21/21
06/21
09:00
06/21/21
09:00
MRO

Marathon Oil

$12.58 /

-0.3 (-2.33%)

BofA analyst Doug Leggate…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRO Marathon Oil
$12.58 /

-0.3 (-2.33%)

MRO Marathon Oil
$12.58 /

-0.3 (-2.33%)

08:04 Today BofA
Marathon Oil upgraded to Neutral from Underperform at BofA
06/18/21 Morgan Stanley
Marathon Oil upgraded to Equal Weight from Underweight at Morgan Stanley
06/10/21 RBC Capital
Marathon Oil upgraded to Outperform at RBC Capital on updated oil price forecast
06/10/21 RBC Capital
Marathon Oil upgraded to Outperform from Sector Perform at RBC Capital
MRO Marathon Oil
$12.58 /

-0.3 (-2.33%)

MRO Marathon Oil
$12.58 /

-0.3 (-2.33%)

MRO Marathon Oil
$12.58 /

-0.3 (-2.33%)

MRO Marathon Oil
$12.58 /

-0.3 (-2.33%)

Initiation
ZipRecruiter initiated with a Neutral at JPMorgan » 09:00
06/21/21
06/21
09:00
06/21/21
09:00
ZIP

ZipRecruiter

$21.26 /

+0.56 (+2.71%)

JPMorgan analyst Doug…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ZIP ZipRecruiter
$21.26 /

+0.56 (+2.71%)

08:25 Today Evercore ISI
Evercore ISI starts 'differentiated' ZipRecruiter at Outperform
07:33 Today Raymond James
ZipRecruiter initiated with a Strong Buy at Raymond James
07:02 Today Raymond James
ZipRecruiter initiated with a Strong Buy at Raymond James
06:58 Today William Blair
ZipRecruiter initiated with an Outperform at William Blair
  • 26
    May
ZIP ZipRecruiter
$21.26 /

+0.56 (+2.71%)

Hot Stocks
AppHarvest starts construction on two new indoor firms » 08:59
06/21/21
06/21
08:59
06/21/21
08:59
APPH

AppHarvest

$15.28 /

-0.3 (-1.93%)

AppHarvest announced the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
APPH AppHarvest
$15.28 /

-0.3 (-1.93%)

APPH AppHarvest
$15.28 /

-0.3 (-1.93%)

06/16/21 Barclays
AppHarvest initiated with an Overweight at Barclays
02/11/21
Fly Intel: Top five analyst initiations
02/11/21 Cowen
AppHarvest appealing to food and water investors, Cowen starts with Outperform
02/11/21 Cowen
AppHarvest initiated with an Outperform at Cowen
APPH AppHarvest
$15.28 /

-0.3 (-1.93%)

APPH AppHarvest
$15.28 /

-0.3 (-1.93%)

APPH AppHarvest
$15.28 /

-0.3 (-1.93%)

Initiation
Singular Genomics initiated with an Overweight at JPMorgan » 08:58
06/21/21
06/21
08:58
06/21/21
08:58
OMIC

Singular Genomics

$23.90 /

-0.34 (-1.40%)

JPMorgan analyst Tycho…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
OMIC Singular Genomics
$23.90 /

-0.34 (-1.40%)

08:56 Today BofA
Singular Genomics initiated with a Neutral at BofA
06:13 Today Cowen
Singular Genomics initiated with an Outperform at Cowen
04:48 Today Goldman Sachs
Singular Genomics Systems initiated with a Buy at Goldman Sachs
  • 27
    May
OMIC Singular Genomics
$23.90 /

-0.34 (-1.40%)

Earnings
AMMO sees Q4 revenue $24M, consensus $23.95M  08:58
06/21/21
06/21
08:58
06/21/21
08:58
POWW

AMMO

$7.94 /

+0.545 (+7.37%)

 
ShowHide Related Items >><<
POWW AMMO
$7.94 /

+0.545 (+7.37%)

POWW AMMO
$7.94 /

+0.545 (+7.37%)

04/22/21
Fly Intel: Top five analyst initiations
04/22/21 Lake Street
AMMO initiated with a Buy at Lake Street
04/08/21 Roth Capital
AMMO initiated with a Buy at Roth Capital
POWW AMMO
$7.94 /

+0.545 (+7.37%)

  • 12
    Mar
  • 01
    Dec
POWW AMMO
$7.94 /

+0.545 (+7.37%)

POWW AMMO
$7.94 /

+0.545 (+7.37%)

Earnings
AMMO reaffirms 2021 revenue view $62M, consensus $62.25M » 08:57
06/21/21
06/21
08:57
06/21/21
08:57
POWW

AMMO

$7.94 /

+0.545 (+7.37%)

AMMO is pleased to be…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
POWW AMMO
$7.94 /

+0.545 (+7.37%)

POWW AMMO
$7.94 /

+0.545 (+7.37%)

04/22/21
Fly Intel: Top five analyst initiations
04/22/21 Lake Street
AMMO initiated with a Buy at Lake Street
04/08/21 Roth Capital
AMMO initiated with a Buy at Roth Capital
POWW AMMO
$7.94 /

+0.545 (+7.37%)

  • 12
    Mar
  • 01
    Dec
POWW AMMO
$7.94 /

+0.545 (+7.37%)

POWW AMMO
$7.94 /

+0.545 (+7.37%)

Hot Stocks
EXL Health partners with REVELOHEALTH for revenue cycle management » 08:57
06/21/21
06/21
08:57
06/21/21
08:57
EXLS

ExlService

$105.72 /

+0.84 (+0.80%)

EXL announced the launch…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EXLS ExlService
$105.72 /

+0.84 (+0.80%)

EXLS ExlService
$105.72 /

+0.84 (+0.80%)

05/12/21 BofA
ExlService upgraded to Neutral from Underperform at BofA
03/01/21 Citi
ExlService price target raised to $92 from $90 at Citi
12/11/20 JPMorgan
ExlService price target raised to $92 from $89 at JPMorgan
08/17/20 JPMorgan
ExlService price target raised to $77 from $66 at JPMorgan
EXLS ExlService
$105.72 /

+0.84 (+0.80%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.